Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Cancer Cell

Volumn 5, Issue 4, 2004, Pages 317-328

  Franklin, Matthew C ^a   Carey, Kendall D ^a   Vajdos, Felix F ^a,c   Leahy, Daniel J ^b   De Vos, Abraham M ^a   Sliwkowski, Mark X ^a  

^a GENENTECH INC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CELL STRAIN COS7; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; DRUG MECHANISM; GENE MUTATION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 1842605531     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00083-2     Document Type: Article

References (50)

1. Agus D.B., Akita R.W., Fox W.D., Lofgren J.A., Higgins B., Maiese K., Scher H.I., Sliwkowski M.X. A potential role for activated HER-2 in prostate cancer. Semin. Oncol. 27:2000;76-83.
2. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K.et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2:2002;127-137.
3. Aroian R.V., Koga M., Mendel J.E., Ohshima Y., Sternberg P.W. The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. Nature. 348:1990;693-699.
4. Arteaga C.L. ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 284:2003;122-130.
5. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell. 12:2003;541-552.
6. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89:1992;4285-4289.
7. Carter P., Fendly B.M., Lewis G.D., Sliwkowski M.X. Development of Herceptin. Breast Disease. 11:2000;103-111.
8. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 297:2002;1330-1333.
9. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:2003;756-760.
10. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:2000;443-446.
11. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:1999;2639-2648.
12. Eigenbrot C., Randal M., Presta L., Carter P., Kossiakoff A.A. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J. Mol. Biol. 229:1993;969-995.
13. Falls D.L. Neuregulins. functions, forms, and signaling strategies Exp. Cell Res. 284:2003;14-30.
14. Fendly B.M., Winget M., Hudziak R.M., Lipari M.T., Napier M.A., Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50:1990;1550-1558.
15. Ferguson K.M., Darling P.J., Mohan M.J., Macatee T.L., Lemmon M.A. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J. 19:2000;4632-4643.
16. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell. 11:2003;507-517.
17. Fry D.W. Mechanism of action of erbB tyrosine kinase inhibitors. Exp. Cell Res. 284:2003;131-139.
18. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A.et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 110:2002;763-773.
19. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell. 11:2003;495-505.
20. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
21. Groenen L.C., Walker F., Burgess A.W., Treutlein H.R. A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer? Biochemistry. 36:1997;3826-3836.
22. Hanks S.K., Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily. kinase (catalytic) domain structure and classification FASEB J. 9:1995;576-596.
23. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284:2003;99-110.
24. Hudziak R.M., Ullrich A. Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum. J. Biol. Chem. 266:1991;24109-24115.
25. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. Epidermal growth factor receptor. mechanisms of activation and signalling Exp. Cell Res. 284:2003;31-53.
26. Kelley R.F., O'Connell M.P., Carter P., Presta L., Eigenbrot C., Covarrubias M., Snedecor B., Bourell J.H., Vetterlein D. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. Biochemistry. 31:1992;5434-5441.
27. Livneh E., Glazer L., Segal D., Schlessinger J., Shilo B.Z. The Drosophila EGF receptor gene homolog. conservation of both hormone binding and kinase domains Cell. 40:1985;599-607.
28. Mann M., Sheng H., Shao J., Williams C.S., Pisacane P.I., Sliwkowski M.X., DuBois R.N. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 120:2001;1713-1719.
29. Mendoza N., Phillips G.L., Silva J., Schwall R., Wickramasinghe D. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res. 62:2002;5485-5488.
30. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:2001;4744-4749.
31. Murali R., Brennan P.J., Kieber-Emmons T., Greene M.I. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases. oligomerization of kinase domains Proc. Natl. Acad. Sci. USA. 93:1996;6252-6257.
32. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallogr. D. 53:1997;240-255.
33. Navaza J. AMoRe. an Automated Package for Molecular Replacement Acta Crystallogr. A. 50:1994;157-163.
34. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:2002;775-787.
35. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network. receptor heterodimerization in development and cancer EMBO J. 19:2000;3159-3167.
36. Paborsky L.R., Fendly B.M., Fisher K.L., Lawn R.M., Marks B.J., McCray G., Tate K.M., Vehar G.A., Gorman C.M. Mammalian cell transient expression of tissue factor for the production of antigen. Protein Eng. 3:1990;547-553.
37. Paik S., Liu E.T. HER2 as a predictor of therapeutic response in breast cancer. Breast Disease. 11:2000;91-102.
38. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer. prognostic factor, predictive factor, and target for therapy Stem Cells. 16:1998;413-428.
39. Schaefer G., Akita R.W., Sliwkowski M.X. A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2. J. Biol. Chem. 274:1999;859-866.
40. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225.
41. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182.
42. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
43. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:2002;46265-46272.
44. Stein R.A., Staros J.V. Evolutionary analysis of the ErbB receptor and ligand families. J. Mol. Evol. 50:2000;397-412.
45. Vajdos F.F., Adams C.W., Breece T.N., Presta L.G., de Vos A.M., Sidhu S.S. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J. Mol. Biol. 320:2002;415-428.
46. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M.et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:2002;719-726.
47. Wadsworth S.C., Vincent W.S. 3rd, Bilodeau-Wentworth D. A Drosophila genomic sequence with homology to human epidermal growth factor receptor. Nature. 314:1985;178-180.
48. Ward C.W., Garrett T.P. The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules. BMC Bioinformatics. 2:2001;4.
49. Werther W.A., Gonzalez T.N., O'Connor S.J., McCabe S., Chan B., Hotaling T., Champe M., Fox J.A., Jardieu P.M., Berman P.W., Presta L.G. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 157:1996;4986-4995.
50. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:2001;127-137.